General form of registration statement for all companies including face-amount certificate companies

Warrants

v3.21.2
Warrants
3 Months Ended 12 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Evolv Technologies Holdings Inc [Member]    
Warrants

10. Warrants

In February 2019, in connection with the 2019 Term Loan Advance, the Company issued a warrant to SVB for the purchase of 75,000 shares of common stock at an exercise price of $0.09 per share (the “2019 SVB Common Stock Warrant”). The 2019 SVB Common Stock Warrant was immediately exercisable and expires in February 2029. The warrant was classified as an equity instrument and recorded at its fair value of less than $0.1 million on the date of issuance through additional paid-in-capital.

In March 2020, in connection with the 2020 Term Loan Advance, the Company issued a warrant to SVB for the purchase of 740,991 shares of common stock at an exercise price of $0.15 per share (the “2020 SVB Common Stock Warrant”). The 2020 SVB Common Stock Warrant was immediately exercisable and expires in March 2030. The warrant was classified as an equity instrument and recorded at its fair value of less than $0.1 million on the date of issuance through additional paid-in-capital.

              In December 2020, in connection with the JPM Term Loan, the Company issued a warrant to JPM for the purchase of 1,000,000 shares of common stock at an exercise price of $0.16 per share (the “2020 JPM Common Stock Warrant”). The 2020 JPM Common Stock Warrant was immediately exercisable and expires in December 2030. The warrant was classified as an equity instrument and recorded at its fair value of $0.1 million on the date of issuance through additional paid-in-capital.

As of March 31, 2021 and December 31, 2020, warrants to purchase the following classes of Preferred Stock and Common Stock outstanding consisted of the following in the table below.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

March 31, 2021 and December 31, 2020

 

 

 

 

 

 

 

 

 

 

Shares Issuable

 

Weighted

 

 

 

 

Contractual

 

Underlying

 

 

 

 Upon

 

 Average

 

 

 

 

Term

 

 Equity

 

Balance Sheet

 

Exercise of

 

 Exercise

 

 

Issuance Date

 

 (in years)

 

 Instrument

 

 Classification

 

 Warrant

 

 Price

 

 

March 17, 2014

    

10

    

Common stock

    

Liability

    

250,000

    

$

0.09

 

 

September 28, 2016

 

10

 

Preferred Stock

 

Temporary Equity

 

2,686,246

 

$

0.001

 

 

July 5, 2017

 

10

 

Common stock

 

Equity

 

375,000

 

$

0.09

 

 

February 12, 2019

 

10

 

Common stock

 

Equity

 

75,000

 

$

0.09

 

 

March 30, 2020

 

10

 

Common stock

 

Equity

 

740,991

 

$

0.15

 

 

December 3, 2020

 

10

 

Common stock

 

Equity

 

1,000,000

 

$

0.16

 

 

 

 

 

 

 

 

 

 

5,127,237

 

 

 

 

 

 

As a result of changes in the fair value of these warrants, the Company recorded other expense of $0.7 million and $0 for the three months ended March 31, 2021 and 2020, respectively.

9.     Warrants

In February 2019, in connection with the 2019 Term Loan Advance, the Company issued a warrant to SVB for the purchase of 75,000 shares of common stock at an exercise price of $0.09 per share (the “2019 SVB Common Stock Warrant”). The 2019 SVB Common Stock Warrant was immediately exercisable and expires in February 2029. The warrant was classified as an equity instrument and recorded at its fair value of less than $0.1 million on the date of issuance through additional paid-in-capital.

In March 2020, in connection with the 2020 Term Loan Advance, the Company issued a warrant to SVB for the purchase of 740,991 shares of common stock at an exercise price of $0.15 per share (the “2020 SVB Common Stock Warrant”). The 2020 SVB Common Stock Warrant was immediately exercisable and expires in March 2030. The warrant was classified as an equity instrument and recorded at its fair value of less than $0.1 million on the date of issuance through additional paid-in-capital.

In December 2020, in connection with the JPM Term Loan, the Company issued a warrant to JPM for the purchase of 1,000,000 shares of common stock at an exercise price of $0.16 per share (the “2020 JPM Common Stock Warrant”). The 2020 JPM Common Stock Warrant was immediately exercisable and expires in December 2030. The warrant was classified as an equity instrument and recorded at its fair value of $0.1 million on the date of issuance through additional paid-in-capital.

As of December 31, 2020 and 2019, warrants to purchase the following classes of Preferred Stock and Common Stock outstanding consisted of the following:

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2020

 

 

Contractual

 

 

 

 

 

Shares Issuable

 

Weighted

 

 

Term

 

Underlying Equity

 

Balance Sheet

 

Upon Exercise

 

Average

Issuance Date

    

(in years)

    

Instrument

    

Classification

    

of Warrant

    

Exercise Price

March 17, 2014

 

10

 

Common stock

 

Liability

 

250,000

 

$

0.09

September 28, 2016

 

10

 

Preferred Stock

 

Temporary Equity

 

2,686,246

 

$

0.001

July 5, 2017

 

10

 

Common stock

 

Equity

 

375,000

 

$

0.09

February 12, 2019

 

10

 

Common stock

 

Equity

 

75,000

 

$

0.09

March 30, 2020

 

10

 

Common stock

 

Equity

 

740,991

 

$

0.15

December 3, 2020

 

10

 

Common stock

 

Equity

 

1,000,000

 

$

0.16

 

 

 

 

  

 

  

 

5,127,237

 

 

  

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2019

 

 

Contractual

 

 

 

 

 

Shares Issuable

 

Weighted

 

 

Term

 

Underlying Equity

 

Balance Sheet

 

Upon Exercise of

 

Average

Issuance Date

    

(in years)

    

Instrument

    

Classification

    

Warrant

    

Exercise Price

March 17, 2014

 

10

 

Common stock

 

Liability

 

250,000

 

$

0.09

September 28, 2016

 

10

 

Preferred Stock

 

Temporary Equity

 

2,686,246

 

$

0.001

July 5, 2017

 

10

 

Common stock

 

Equity

 

375,000

 

$

0.09

February 12, 2019

 

10

 

Common stock

 

Equity

 

75,000

 

$

0.09

 

 

 

 

  

 

  

 

3,386,246

 

 

  

 

As a result of changes in the fair value of these warrants, the Company recorded other income (expense) of less than $0.1 million and less than $0.1 million for the years ended December 31, 2020 and 2019, respectively.